Posted 1/4/2021
Thermaquil, Inc. is a Philadelphia, PA-based Biotechnology Company, established in 2017. The company was assisted by the IPart through our Federal Marketing Assistance (FMA) Phase II Technical Assistance Program and received a $5,000 award from IPart to enhance and improve their Phase II submission.
Thermaquil received a Phase II, SBIR Award from the NSF for $1,000,000 to execute on the following proposed project:
SBIR Phase II Project Abstract: The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the development of a simple wearable device to manage pain. Despite advances in new therapies, addictive narcotic medications still remain a widely utilized method to control pain for many conditions. The proposed technology represents a new noninvasive approach to blocking nerve conduction without reliance on drugs. The device can be easily adapted to treat any condition wherein pain is transmitted along nerves close to the skin surface. This work will demonstrate feasibility of a novel therapeutic approach to pain management without risk of drug dependence or addiction. This Small Business Innovation Research (SBIR) Phase II project will fully develop a human wearable thermal nerve block device for treating severe head and neck pain by blocking nerves in the occipital region. Occipital pain is driven by a number of physiological and pathological causes, and many patients fail to find adequate pain relief solutions that allow them to continue their daily activities, thus leading to poor quality of life with reduced productivity and socialization. The device developed in this project will thermally modulate the occipital region in such a way as to initiate and then maintain a drug-free nerve block. This award reflects NSF’s statutory mission and has been deemed worthy of support through evaluation using the Foundation’s intellectual merit and broader impacts review criteria.
More Information on their award can be found HERE
